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Young women with a prosthetic heat? valve often wish to bear 
children (1). Pregnancy in such patients is associated with 
increased risk due to various causes, including increased blood 
volume and hemodynamic burden, hypercoagulable state of 
pregnancy leading to increased incidence of thromboemboiic 
events and the exposure of the fetus to cardiovascular drugs 
required to treat maternal disease. Oral anticoaguian! agents 
have been considered contraindicated in pregnancy because of 
theii reported teratogenic effect and resulting abnormalities. 
In contrast, heparin does not cross the placenta because of its 
large molecule, and recent experience (2) in a large number of 
patients who received heparin during pregnancy has shown a 
normal fetal and neonatal outcome without an increase in 
maternal bleeding complications. Although subclinical reduc- 
tion in bone density is a potential consequence of long-term 
heparin therapy in pregnancy, it is usually reversible, and the 
risk of symptomatic bone fracture is small (3). For ah these 
reasons, it is not surprising that the use of heparin has been 
preferred during pregnancy in patients requiring anticoagula- 
tion therapy (4). In thii issue of the Journal, Sabsaar et al. (5) 
describe their prospective experience with 40 pregnancies in 37 
women with prosthetic heart valves who received subcutaneous 
heparin from the 6th week to the end of the 12th week and for 
the last 2 weeks of gestation. The authors report fatal valve 
thrombosii during heparin therapy in two cases and conclude 
that subcutaneous heparin is not effective in the prevention of 
mechanical vaIve thrombosis during pregnancy. On the basis of 
their 8ndings, the authors recommend the use of oral antico- 
agtdation throughout pregnancy with a change to heparin only 
during the last 2 weeks of gestation. These group of investiga- 
tors have had a long-standing interest in the management of 
pregnant patients with prosthetic heart valves. Their previous 
publications (6,7) had a substantial impact on the care of such 
patiems, and theii present report is likely to have a Similar 
e&et. For this reason, the results of the study should be 
analyzed very carefuhy and in content of other avaihtble data. 
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Considering the important clinical implications of their recom- 
mendations, Salazar et al. (5) could be criticized for overinter- 
preting information obtained in only a small number of 
patients. The authors have used the results of a recent Euro- 
pean survey (8) that evaluated 12 cases of mechanical vaIve 
thrombosis during pregnancy, IL of which occurred during 
subcutaneous heparin therapy, to defend their conclusions. 
Although these data may indeed suggest failure of subcutane- 
ous heparin to provide adequate protection against valve 
thrombosis during pregnancy, the resnits of such surveys are 
unfortunately limited by the retrospective design and the 
inherent susceptibility to providing incomplete and biased 
information (3). 
Both the studies by Saiazar et al. (5) and Sbarouni et al. (8) 
reported the occurrence of valve thrombosis in patients with 
older generation mechanical prosthesis, such as Starr-Edwards 
and Bjork-Shiley valves, and in all cases the prosthetic valve 
involved was in the mitral position. Should the recommenda- 
tions to use Coumadin during most of the pregnancy, including 
the first trimester, be extended to newer, less thrombogenic 
prosthetic heart valves and to valves in the aortic position? The 
answer to these questions is difficult, mairdy for tack of 
sufficient information. However, Sareli et al. (9) reported a low 
incidence of thromboembohsm despite inadequate anticoagu- 
lation during 50 pregnancies in women with 60 mechanical 
valves. The majority of these patients bad newer generation 
mechanical prostheses (Medtronic-Hall and St. Jude Medical) 
and were treated with Coumadin during the first two trimesters 
of gestatiou and heparin during the last trimester. Measured 
prothrombin ratio was found to be within the therapeutic 
range in only 39% of cases. These data may indicate a lower 
likelihood of thromboembolii events during pregnancy in 
patients with newer generation prosthetic heart valves. 
A reported high rate of valve thrombosis during heparin 
therapy may be due to inadequate heparin dose or lack of 
stringent monitoring of activated partial thromboplastin time 
(aPIT). Although the authors state that vaIve thrombosis 
occurred despite adequate heparin dosing, data are not pm- 
vided. In addition, the minimal target aPTI ratio of 1.5 used by 
these investigators has recently been suggested to be too low 
(3). Similarly, no information regarding adequacy of heparin 
dose and aPTI monitoring in cases with valve thrombosis is 
provided by Sbarouni et al. (9). In addition, anecdotal infor- 
mation clearly demonstrates that valve thrombosis during 
pregnancy is not unique to heparin and can also occur in 
patients receiving Coumadin theray, especiahy when ade- 
quate monitoring is not available (lti-12). 
Sbarouni et al. (9) repoited no embryopathies in a group of 
46 women who were treated with warfarin during the Iirst 
gestational trimester and state that embryopatby is rare when 
a dose of warfarin is well controUed. In con- a can&I 
evahmtion in two other studies resulted in diignosing signs of 
embryopothy in as many as 29% (6) and 67% (13) of newborns, 
respectkrety. The authors (5) indicate that many cItiIdren with 
coumadin embryopathy have only minor abnormalities. How- 
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ever, this can hardly be used as reassurance because the 
severity of the syndrome in an individual case is unpredictable, 
and many women are more likely to accept a possible increased 
risk to themselves before accepting the risk of “only” minor 
abnormalities in their children (1). In recent weeks, we con- 
sulted on two pregnant patients with prosthetic valves. The first 
had a Bjiirk-Shiley valve in the mitral position due to an 
episode of bacterial endocarditis and the second a St. Jude 
valve in the tricuspid position due to Ebsteio’s anomaly. The 
latter patient developed valve thrombosis during gestation and 
was treated successfully with urokinase. Both patients and their 
physicians were informed of the reports by Sahxar et al. (7) 
and Sbarouni et al. (8), and both elected to be treated with 
heparin. This experience suggests the need for an alternative 
drug regimen for high risk patients xho may not wish to 
receive Coumadin during the tirst gestational trimester. 
The use of a bioprosthetic valve can obviate the need for 
prolonged anticoagulation and, therefore, may seem a more 
appropriate choice in a woman with no other reason for 
anticoagulation during the childbearing age. However, several 
reports (5,8) have provided clear evidence for pregnancy- 
related accelerated bioprosthetic valve failure. Thirty-five per- 
cent of valves in the study by Sbarouni et al. (8) and 47% of 
valves in the study by Badduke et al. (14) demonstrated 
pregnancy-related stmctural deterioration reqiring valve re- 
operation. Although the risk of mortahty associated with a 
valve re-replacement has not been systematically evaluated in 
women of childbearing age, it has been reported to be 8.7% by 
one group (14). 
Summary and recommemIatIans. Anticoagulation in a pa- 
tient with a mechanical heart valve during pregnancy presents 
a double jeopardy with risk both to the mother and the fetus. 
The study by Salazar et al. (5) and a recently published survey 
(8) have reported increased incidence of vaIve thrombosis in 
women treated with subcutaneous beparin and led to the 
recommendations to use Coumadm throughout pregnancy. 
However, exposure of the fetus to Coumadii may result in 
severe fetal consequences due to teratogenic effects and intra- 
cranial bleeding (4). The data presented and other available 
in Jrmation are limited by either a small number of patients or 
by a retrospective design and possible selective and incomplete 
reporting. Any recommendations at the present time, there- 
fore, cannot be detinitive, are temporary and need to be 
further validated. Women with older generation prosthetic 
valves in the mitral position should be informed of the 
potential risk of valve thrombosis with heparin therapy and 
should consider the use of Gxmmdin thmqhout gestation 
with heparin before deEvery. In high risk women who choose 
not to take Coumadin during C.te first trimester, in-hospital 
wntinuous intravenous heparin treatmen& at least between 
weeks 6 and 12, seems just&d. In patients with older gener- 
ationprostheticvalvesbutintheaorticpn6itionandthosewith 
newer generation heart vahe in any positioih subattt 
hepminshouldbeusedduringthe&sttrimesterandintheM 
partofgestation.ThedoseofheparinshouIdbeadjustedto 
proIongthemidintervalaIlT~tothreethnesa?ntNi 
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value, and adequacy of anticoagulation should be monitored at 
least once every 1 to 2 weeks. Administration of heparin by 
subcutaneou< infusion with a programmable pump has been 
demonstrate* to achieve mom even control with fewer com- 
plications than intermittent subcutaneous injection technique 
(1.5) and should be considered in patients with prosthetic 
valves. 
Low molecular weight heparin may be an attractive drug for 
use during pregnancy. Similar to standard unfractionated 
heparin, it does not cross the placenta, and at the same time, 
it may provide additional benefits, including reduced incide..ce 
of heparin-induced thrombocytopenia, osteoporosis and bleed- 
ing complications, and no blood test is required to monitor its 
safety (16). The drug has been used effectively and safely to 
treat deep vein thrombosis during pregnancy, but data in 
patients with a prosthetic valve are not avai!able. Because a 
small dose of aspirin is safe during pregnancy (3), it may be 
used in addition to anticoagulation to maxim& the antithrom- 
botic effect The concomitant use of diidamole is not 
recommended because of high fetal loss demonstrated in one 
study (9). 
Premature labor frequently occurs in women with pros- 
thetic heart vatvcs. In the study by Sa’azar et al. (5) 36% of the 
neonates were born before the 37th week of gestation, and one 
neonate died of cerebral hemorrhage that ccctnred during 
labor due to Cixrmadin treatment. These data suggest the need 
to substitute Coumadin with a therapeutic dose of heparin no 
later than 35 or 36 weeks of gestation to avoid the onset of 
labor during Coumadin therapy. In patients with older gener- 
ation mitral prosthesis in the hospital iatravenous heparin 
therapy until term may be advisable to minimize the risk of 
vaIvethmmhoGiCesareansectionshouIdbeusedasamode 
of delivery in patients who go into labor during treatment with 
oral anthagtdation to prevent fetal cerebral hemorrhage 
during vaginal delivery. 
The present study by Salazar et al. (5) is another attempt to 
resolve the dilhcult issue of anticoag&tion in patients with a 
mecha&alheartvalveduringpregnaq Howtxer, this at- 
tempt fails to provide clear guidelines for the treatment of nrh 
patients. In addition, the recommendations by the authors for 
the use of Coumadin, a drug dedared by its manufacturer 
contraindicated during pregnanq, also present a double jeep 
ardyforphyGc&swhomaybebIamedforusingthedrugor 
for not using it during pregnaq. A strong plea should 
therefore be made for a large, prospective. randomii and 
well controlled study to evaluate the eihcacy and safety of 
various antiatqulation regimens in women with pros&tic 
heart valves during pregnancy. 
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